Your search for tofacitinib returned 75 results

For patients with rheumatoid arthritis, a novel oral Janus kinase inhibitor, tofacitinib, is associated with reduced symptoms when used as monotherapy or in addition to background methotrexate.

A total of 18.5% patients taking tofacitinib experienced a remission of their condition in 8 weeks compared to just 8.2% of patients receiving placebo.

The GIDAC recommendations are provided to the FDA but they are not binding. The FDA has set a target PDUFA action date of June 2018.

The approval was based on data from a phase 3 study which evaluated tofacitinib in adults with active AS who had an inadequate response to at least 2 NSAIDs.

Tofacitinib is superior for patients with inadequate response to TNF inhibitors or conventional DMARDs

The addition of tofacitinib to rheumatoid arthritis (RA) treatment regimens improves patient response to non-biologic disease-modifying antirheumatic drugs (DMARDs).

Tofacitinib, an oral inhibitor of Janus kinase 1, 2, and 3, can reduce disease severity and induce remission better than a placebo in patients with moderately to severely active ulcerative colitis.

The ORAL Shift study enrolled 694 RA patients who were inadequate responders to methotrexate alone.

The Food and Drug Administration (FDA) has approved changes to the prescribing information for tofacitinib to include new warnings, including a Boxed Warning, regarding an increased risk of blood clots and death associated with the 10mg twice daily regimen.  The update comes after a review of data from an ongoing safety clinical trial of tofacitinib…

Pfizer announced top-line results from OCTAVE Sustain, the third Phase 3 study of Xeljanz (tofacitinib citrate) for the potential treatment of patients with moderately to severely active ulcerative colitis (UC).